Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bardoxolone methyl - Biogen

Drug Profile

Bardoxolone methyl - Biogen

Alternative Names: Bard - Biogen; Bardoxolone methyl - Abbott/Kyowa Hakko Kirin/Biogen; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Biogen; Kyowa Kirin; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antihypertensives; Antineoplastics; Antivirals; Carboxylic acids; Hepatoprotectants; Nitriles; Obesity therapies; Small molecules; Triterpenes; Urologics
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Hereditary nephritis; Autosomal dominant polycystic kidney disease; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autosomal dominant polycystic kidney disease; COVID 2019 infections; Diabetic nephropathies; Haematological malignancies; Hereditary nephritis; Liver disorders; Malignant melanoma; Non-alcoholic steatohepatitis; Obesity; Pancreatic cancer; Pulmonary arterial hypertension; Pulmonary hypertension; Renal failure; Solid tumours; Viral hepatitis

Most Recent Events

  • 26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
  • 05 Jun 2023 Discontinued - Phase-III for Renal failure (In adolescents, In children, In the elderly, In adults) in Australia (PO)
  • 05 Jun 2023 Discontinued - Phase-III for Renal failure (In adolescents, In children, In the elderly, In adults) in France (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top